월경전증후군(PMS) 및 월경 건강보조제 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 제품 유형, 적응증별, 제형별, 최종 용도별, 지역별 및 경쟁(2021-2031년)

The Global Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market is projected to expand from USD 21.45 Billion in 2025 to USD 29.68 Billion by 2031, achieving a compound annual growth rate (CAGR) of 5.56%. These supplements typically consist of specialized nutraceutical formulations containing vitamins, minerals, and botanical extracts intended to alleviate the physiological and psychological symptoms linked to the menstrual cycle. The market's growth is primarily sustained by the increasing global incidence of premenstrual disorders and a fundamental consumer shift toward preventive, non-pharmaceutical health management; unlike fleeting market trends such as new delivery formats, these drivers indicate a structural commitment to long-term reproductive wellness and a persistent demand for natural substitutes to traditional pain medications.

A major obstacle hindering wider market scalability is the intricate regulatory environment, where inconsistent standards for substantiating health claims prevent manufacturers from advertising specific therapeutic benefits without rigorous clinical proof. This absence of global regulatory alignment frequently creates difficulties in product distribution and marketing compliance. Illustrating the increasing dependence on ingredients that target specific symptoms, the Council for Responsible Nutrition reported in 2024 that the usage of magnesium, a critical nutrient employed to manage menstrual cramps and mood swings, increased to 23 percent among supplement consumers.

Market Driver

The growing consumer awareness and the destigmatization surrounding menstrual health are fundamentally transforming market dynamics by fostering open discussions about symptoms that were historically normalized or ignored. This cultural evolution has shifted the focus of menstrual care from simple hygiene to comprehensive management, encouraging women to proactively seek nutraceutical solutions to maintain their well-being and productivity. A direct link is emerging between this increased health literacy and product consumption, as buyers graduate from general wellness items to targeted remedies; for instance, The Vitamin Shoppe's 'Health & Wellness Trend Report 2024' from June 2024 noted a 12 percent increase in sales of specialized PMS formulas over the previous year, underscoring the rising demand for symptom-specific management.

At the same time, a growing preference for natural, organic, and plant-based ingredients is propelling the development of clean-label supplements as consumers move away from synthetic pharmaceuticals. This trend prioritizes botanical extracts and bioavailable minerals, which are viewed as safer alternatives for long-term hormonal regulation compared to conventional pain relievers. According to Holland & Barrett's 'Wellness Trends Report 2025' released in November 2024, online searches for Magnesium Glycinate-a mineral form valued for its gentle absorption and muscle-relaxing effects during menstruation-surged by 180 percent. This appetite for high-quality, non-pharmacological choices is fueling broader category expansion, as evidenced by Haleon's '2024 Full year results' from February 2025, which reported a 7.6 percent growth in organic revenue for their Vitamins, Minerals and Supplements division.

Market Challenge

The intricate regulatory environment and inconsistent standards regarding the substantiation of health claims create a significant barrier to scalability within the Global Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market. Since dietary supplement regulations vary widely across different regions, manufacturers encounter major challenges in standardizing product formulations and marketing communications. In numerous jurisdictions, companies are legally prohibited from making specific therapeutic assertions-such as claiming a product alleviates menstrual cramps or reduces hormonal mood swings-without expensive and extensive clinical validation, which prevents brands from fully conveying the efficacy of their botanical and nutrient-based formulas to consumers and ultimately suppresses sales volume and market penetration.

This regulatory constraint is especially restrictive given the growing consumer interest in specialized functional ingredients. As reported by the Council for Responsible Nutrition in 2024, the usage of ashwagandha, a botanical extract frequently used for stress and mood regulation, reached 8 percent among supplement users. Although consumer demand for such natural alternatives is clear, the inability of manufacturers to explicitly label these products with their direct PMS-related benefits due to rigorous substantiation rules hinders product differentiation; consequently, the market faces difficulties in translating this rising ingredient awareness into broader category growth, as consumers often remain reluctant to buy products that are forced to carry vague or diluted health claims.

Market Trends

The widespread adoption of cycle-syncing supplement regimens is fundamentally changing product development, with consumers increasingly moving away from static multivitamins in favor of phase-specific formulations designed for the follicular, ovulatory, luteal, and menstrual phases. This trend goes beyond simple nutrient replenishment, fostering demand for sophisticated 28-day kits that synchronize ingredient release profiles-such as increasing magnesium during the luteal phase for mood support or supplementing iron during menstruation-with real-time hormonal changes. This transition from reactive symptom management to proactive hormonal optimization is highlighted by rising digital engagement; specifically, The Drum reported in January 2025, in the article 'Why are women forced to turn to TikTok for menstrual advice? Where are the brands?', that Google Trends data showed a 124 percent year-on-year increase in consumer interest regarding cycle syncing, indicating a substantial opportunity for brands to educate and engage this informed demographic.

Concurrently, the incorporation of AI-driven personalized nutrition plans is transforming business models by turning sporadic buyers into long-term subscribers through data-based customization. By employing algorithmic quizzes to assess individual symptom patterns and biometric data, manufacturers can now assemble high-precision daily packs that target specific reproductive health objectives, such as managing the perimenopausal transition or PMS severity, thereby increasing perceived value and customer retention. This convergence of technology and health is generating significant financial returns for leading industry players; according to NutraIngredients in July 2024, in the article 'Unilever talks explosive growth of its wellness business', the integration of emerging tools like artificial intelligence combined with a strategic emphasis on women's health categories drove a 20 percent underlying sales growth for the company's Health & Wellbeing Collective.

Key Market Players

• Herbalife International of America, Inc.
• Nature's Bounty
• Amway Corp.
• GNC Holdings, LLC
• USANA Health Sciences, Inc
• GlaxoSmithKline Plc
• MetP Pharma AG
• Archer-Daniels-Midland Company
• Power Gummies
• Looni

Report Scope

In this report, the Global Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market, By Indication

• Perimenopause
• PMS

Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market, By Formulation

• Capsules/Tablets
• Powder
• Softgels
• Other

Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market, By End Use

• Pharmacies/Drug Stores
• Online Sales Channel
• Direct Sales Channel
• Others

Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market.

Available Customizations:

Global Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Perimenopause, PMS)
  • 5.2.2. By Formulation (Capsules/Tablets, Powder, Softgels, Other)
  • 5.2.3. By End Use (Pharmacies/Drug Stores, Online Sales Channel, Direct Sales Channel, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Formulation
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Formulation
      • 6.3.1.2.3. By End Use
  • 6.3.2. Canada Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Formulation
      • 6.3.2.2.3. By End Use
  • 6.3.3. Mexico Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Formulation
      • 6.3.3.2.3. By End Use

7. Europe Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Formulation
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Formulation
      • 7.3.1.2.3. By End Use
  • 7.3.2. France Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Formulation
      • 7.3.2.2.3. By End Use
  • 7.3.3. United Kingdom Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Formulation
      • 7.3.3.2.3. By End Use
  • 7.3.4. Italy Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By Formulation
      • 7.3.4.2.3. By End Use
  • 7.3.5. Spain Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By Formulation
      • 7.3.5.2.3. By End Use

8. Asia Pacific Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Formulation
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Formulation
      • 8.3.1.2.3. By End Use
  • 8.3.2. India Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Formulation
      • 8.3.2.2.3. By End Use
  • 8.3.3. Japan Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Formulation
      • 8.3.3.2.3. By End Use
  • 8.3.4. South Korea Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
      • 8.3.4.2.2. By Formulation
      • 8.3.4.2.3. By End Use
  • 8.3.5. Australia Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication
      • 8.3.5.2.2. By Formulation
      • 8.3.5.2.3. By End Use

9. Middle East & Africa Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Formulation
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Formulation
      • 9.3.1.2.3. By End Use
  • 9.3.2. UAE Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Formulation
      • 9.3.2.2.3. By End Use
  • 9.3.3. South Africa Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Formulation
      • 9.3.3.2.3. By End Use

10. South America Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Formulation
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Formulation
      • 10.3.1.2.3. By End Use
  • 10.3.2. Colombia Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Formulation
      • 10.3.2.2.3. By End Use
  • 10.3.3. Argentina Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Formulation
      • 10.3.3.2.3. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Herbalife International of America, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Nature's Bounty
• 15.3. Amway Corp.
• 15.4. GNC Holdings, LLC
• 15.5. USANA Health Sciences, Inc
• 15.6. GlaxoSmithKline Plc
• 15.7. MetP Pharma AG
• 15.8. Archer-Daniels-Midland Company
• 15.9. Power Gummies
• 15.10. Looni

16. Strategic Recommendations

17. About Us & Disclaimer